Form 4: Cellectar Biosciences CFO Chad J. Kolean Acquires Stock Options Following Stockholder Approval

Chad J. Kolean, CFO of Cellectar Biosciences, acquired stock options for 290,000 shares following stockholder approval of the amended 2021 Stock Incentive Plan.

Summary

• This Form 4 filing reports a transaction by Chad J. Kolean, the Chief Financial Officer of Cellectar Biosciences, Inc.
• On June 14, 2024, Kolean acquired stock options (right to buy) for 290,000 shares of Cellectar Biosciences common stock at an exercise price of $2.65.
• The options were contingently granted on December 15, 2023, and became effective upon stockholder approval of Cellectar's amended 2021 Stock Incentive Plan at the company's 2024 Annual Meeting of Stockholders on June 14, 2024.
• The options vest over three years from December 15, 2023, with one-third vesting on the first anniversary and the remainder vesting in 24 equal monthly installments.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing key personnel.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of the shareholders, potentially incentivizing him to increase shareholder value.

Key Dates

Keywords

Cellectar Biosciences, Chad J. Kolean, Stock Options, Form 4, Insider Trading, CLRB, CFO, Stock Incentive Plan, Vesting